No price history available.

Consensus from external analysts. Not Kvantra's opinion.

Based on consensus from external analysts. Not Kvantra's opinion.

Takara Bio Inc., a subsidiary of Takara Holdings Inc., is a Japan-based biotechnology firm established in Kusatsu in 2002. The company operates globally, with a presence in Japan, China, other Asian countries, the United States, and Europe, focusing on three primary areas: general biotechnology, contract development and manufacturing (CDMO) services, and gene therapy. The company offers a diverse portfolio of scientific products, including a wide array of reagents and specialized instruments. These encompass tools for genetic research and testing, in vitro diagnostic solutions for viral detection (such as those for coronaviruses), analytical reagents, and advanced single-cell analysis systems. They also supply essential reagents for gene expression studies, fluorescent protein series, genome-editing research, iPS cell research, and products for culturing and differentiating stem cells. These offerings are marketed under prominent brands like TaKaRa, Clontech, and Cellartis. In addition to its product line, Takara Bio provides extensive contract services. For regenerative medicine, this includes the production of viral vectors and gene-modified cells, alongside rigorous quality and safety testing, and comprehensive cell banking services. Their gene analysis and testing services cover a broad spectrum, from DNA sequencing and gut microbiome analysis to in-depth profiling of cancer-associated genes and the creation of cell lines through genome editing. Furthermore, Takara Bio is actively engaged in developing foundational platform technologies to support the advancement of biologics, particularly within the field of gene therapy.

• Theravance Biopharma Inc
• Wuhan Keqian Biology Co.,Ltd
• Design Therapeutics, Inc.
• Gubra A/S
• Xiangxue Pharmaceutical Co.,Ltd.
• Annexon, Inc.
• Kura Oncology, Inc.
• Youcare Pharmaceutical Group Co., Ltd.